Elacestrant, a selective estrogen receptor degrader, demonstrated significant improvements in progression-free survival (PFS) ...

Sarah Sammons, MD, discusses some of the challenges seen with different regimens for HER2-positive metastatic breast cancer ...

An expert discusses the next steps for patients with metastatic breast cancer after their disease no longer responds to ...

This infographic, the first in a three-part series, explores the development of resistance to endocrine therapy in ...

A phase 2 study for patients with HR-positive, HER2-negative metastatic breast cancer will be evaluating alisertib plus ...

Novartis Kisqali receives European approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence: Basel Thursday, November 28, 2024, 09: ...

Fact checked by Nick BlackmerA new study found that Black women are more likely to die from breast cancer than white women ...

Findings from the HELEN-006 trial suggest a potential shift in neoadjuvant treatment practices for patients with HER2-positive early breast cancer, specifically using nab-paclitaxel to reduce ...

Both rare and aggressive, triple-negative breast cancer accounts for 10-15% of all breast cancers. Dr. Bhardwaj says, “TNBC ...

Basel: Novartis has announced that the European Commission (EC) has approved Kisqali (ribociclib) in combination with an ...

(RTTNews) - Novartis (NVS) said that the European Commission has approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the adjuvant treatment of patients with hormone receptor ...

Breast cancer is classified into several subtypes depending on the presence or absence of the patient's factors.